Sign in
Taking people in PortugalNo phase

68Ga-FAPI PET/CT scans to look for heart scarring in people with heart failure

Tests a PET/CT scan that looks for heart scarring in adults with heart failure.

Key facts

Who runs it
University of Coimbra
Where
Coimbra, PortugalSee the site
Trial code
Registry title
⁶⁸Ga-FAPI PET/CT for Cardiac Fibrosis in Heart Failure
Status
Recruiting
People taking part
30 people, planned
Started
17 Nov 2025
Expected to end
31 Dec 2028
Type of study
Observational
Treatments tested
  • 68Ga-FAPI PET/CT
Record updated
29 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure caused by dilated cardiomyopathy with weak pumping, or by hypertrophic cardiomyopathy with normal pumping. It uses a special PET/CT scan to look at heart scarring.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Signs and symptoms of heart failure. Either normal pumping (LVEF ≥50%) with signs of stiff heart or hypertrophic cardiomyopathy, or weak pumping (LVEF ≤40%) with dilated cardiomyopathy.
Biomarker or test result
For the hypertrophic group, a genetic diagnosis due to a sarcomeric gene mutation is listed. Elevated natriuretic peptides may be used as evidence of heart changes.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Kidney disease with glomerular filtration rate <30 mL/min/1.73m²
  • Cancer within the past 5 years
  • Implanted cardiac electrical device
  • Hospitalized for heart failure in the last 30 days

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • ≥ 18 years old
  • Signs and symptoms of heart failure (HF)
  • [Preserved left ventricular ejection fraction (LVEF) (≥50%) and Evidence of structural/functional abnormality consistent with diastolic dysfunction/increased ventricular filling pressures, including elevated natriuretic peptides and Imaging diagnosis of hypertrophic cardiomyopathy and Genetic diagnosis of hypertrophic cardiomyopathy due to sarcomeric gene mutation] OR [Reduced LVEF (≤40%) and Imaging diagnosis of dilated cardiomyopathy: left ventricular end-diastolic diameter >58 mm in men and >52 mm in women, and left ventricular volume ≥75 mL/m² in men and ≥62 mL/m² in women, not explained solely by loading conditions]
  • Recent transthoracic echocardiogram (< 3 months)
  • Recent cardiac magnetic resonance imaging (< 3 months)
  • Normal coronary angiogram or computed tomography coronary angiography within 6 months of enrolment

Who cannot take part

  • Chronic kidney disease with glomerular filtration rate <30 mL/min/1.73m²
  • Malignant neoplasms within the past 5 years
  • Significant primary valvular disease
  • Significant atherosclerotic coronary artery disease
  • Grade 2 or 3 arterial hypertension
  • Presence of an implanted cardiac electrical device
  • Recent hospitalization for heart failure (<30 days)
  • Inability to provide informed consent
  • Inability to tolerate the supine position
  • Hemodynamic instability
  • Claustrophobia
  • Pregnant or breastfeeding women

Where in Portugal

  • Faculdade de Medicina da Universidade de CoimbraCoimbra, PortugalContact: João Borges Rosa, MDTaking people

About the trial

What the trial wants to find out

Heart failure (HF) is a clinical syndrome with increasing incidence and prevalence, associated with high morbidity, mortality, and economic impact, despite therapeutic advances.

Read full original descriptionShow less

Myocardial fibrosis is a common feature across different pathophysiological processes and plays a key role in HF development, with growing research interest specifically in non-ischemic dilated cardiomyopathy (HFrEF phenotype) and hypertrophic cardiomyopathy (HFpEF phenotype). Given its potential reversibility with certain drugs, fibrosis is an attractive therapeutic target, requiring non-invasive methods to monitor fibrogenesis and treatment efficacy.

Cardiac magnetic resonance imaging (CMR) is the gold standard for detecting fibrosis but cannot distinguish between active and inactive fibrosis or detect early stages, limitations that may be addressed by gallium-68-labeled fibroblast activation protein inhibitor positron emission tomography/computed tomography (68Ga-FAPI PET/CT).

This single-center, prospective, observational pilot study aims primarily to assess myocardial fibrosis in patients with HFrEF (non-ischemic dilated cardiomyopathy) and a subtype of HFpEF (hypertrophic cardiomyopathy) using 68Ga-FAPI PET/CT compared to CMR.

Secondary objectives include developing 68Ga-FAPI uptake assessment methodologies for future anti-fibrotic therapy studies and correlating fibrosis with serum cardiac biomarkers and cardiovascular events.

The group in the trial

  • patients with HFrEF and HFpEF

    patients with HFrEF (non-ischemic dilated cardiomyopathy) and HFpEF (hypertrophic cardiomyopathy)

    Treatment: 68Ga-FAPI PET/CT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Myocardial Fibrosis in Heart Failure: A Pilot Study With 68Ga-FAPI PET/CT
Plain-language title
68Ga-FAPI PET/CT scans to look for heart scarring in people with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
29 December 2025